Guidant — Merger or Acquisition (November 2005)
12 slides from Guidant's merger presentation, Nov 15, 2005
Slide 1: All-Employee Briefing on Guidant and Johnson & Johnson Announcement
All-Employee Briefing on Guidant and Johnson & Johnson Announcement November 15, 2005
Slide 2: In connection with the proposed merger between Guidant Corporation and Johnson & Johnson, Guidant
In connection with the proposed merger between Guidant Corporation and Johnson & Johnson, Guidant and Johnson & Johnson will file with the SEC a post-effective amendment to their prospectus/proxy statement. This material is not a substitute for the revised prospectus/proxy statement. Investors are u
Slide 3: Today's Announcement: Guidant and J&J Revise Merger Terms
Today’s Announcement Guidant and J&J Revise Merger Terms Guidant and Johnson & Johnson have agreed to revised merger terms to reflect current business conditions: The combination of $33.25 of cash and .493 J&J shares for each Guidant share, a deal valued in excess of $21 billion dollars. The value r
Slide 4: Near term Clarity – A Promising Future
Near term Clarity – A Promising Future Merging with J&J reduces uncertainty associated with our current business conditions. For employees, it provides near-term clarity to move ahead and focus on our patients and customers with the least amount of distraction, and longer-term, the assurance of rewa
Slide 5: Guidant Perspective
Guidant Perspective "The Board believes that it is in the best interest of shareholders to proceed with the merger agreement at the revised terms. Both companies continue to believe that the strategic rationale for a combination is as strong today as when we entered into the original Merger Agreemen
Slide 6: Rationale for the Agreement
Rationale for the Agreement As true today as on December 14, 2004 1. Complementary strengths and combined resources will allow us to better serve needs of patients and physicians 2. Transaction will result in increased investment to accelerate the development of technologically advanced products 3.
Slide 7: Complementary Strengths Will Deliver Sustainable Innovation
Complementary Strengths Will Deliver Sustainable Innovation Outstanding people Outstanding people Patient focus Demonstrated success in creating therapy acceptance Technological expertise Public policy expertise Velocity of product innovation Long-term investment focus Clinical science expertise Bro
Slide 8: Interim Management Plan
Interim Management Plan James M. Cornelius appointed interim Chief Executive Officer of Guidant Mr. Cornelius was elected Chairman of the Board of Directors and its senior executive in September 1994, when Guidant was formed and was instrumental in the successful IPO and subsequent split-off from El
Slide 9: How will the organization work until close?
How will the organization work until close? Nick Valeriani’s leadership team will operate as previously outlined and will continue to work toward close. The integration planning will resume immediately in preparation for Day One and beyond. Mr. Cornelius will lead the Guidant Management Committee, w
Slide 10: Next Steps in the Transaction
Next Steps in the Transaction FTC and other regulatory approvals have been obtained. Information on the revised terms of the merger agreement and special shareholders meeting will be mailed to Guidant shareholders in the near future. Guidant seeks shareholder vote to approve re- negotiated terms in
Slide 11: What does this mean for Guidant Employees?
What does this mean for Guidant Employees? Guidant and Johnson & Johnson remain aligned on the future of the combined entity — Johnson & Johnson continues to recognize and value Guidant’s structure and operating model. Merging with Johnson & Johnson will help the company deal with current business c
Slide 12: Summary – Where do we go from here?
Summary – Where do we go from here? We continue to maintain our focus on our company vision and our day-to-day activities. We realize you have many questions – as always, we are committed to open and frequent communications. In the weeks ahead, both Guidant and Johnson & Johnson management will be v